Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology'
The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature. In the testing cohort, standard molecular risk patients predicted to benefit
Read original at benzinga